Drug Trial Radar · NCT00811954
Comparative Study of Three NNRTI-Sparing HAART Regimens
Last checked: Nov 19, 2026Latest source record: Sep 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,814
Actual
Start
May 2009
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck Sharp & Dohme LLC; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
- First posted
- Dec 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected patients who have never received anti-HIV therapy be treated with a triple drug regimen. The most commonly prescribed and successful regimen contains the medication efavirenz (EFV). However, this regimen may not be an option for everyone, hence alternative regimens are needed. This study was designed to look at how well different combinations of anti-HIV drugs work to decrease the amount of HIV in the blood (viral load) of and allow immune system recovery in people who have never received anti-HIV therapy. This study also examined drug tolerability and safety for the various drug combinations.
Conditions
- HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarateDrug
200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
RaltegravirDrug
400 mg taken orally twice daily. An integrase inhibitor (INI).
DarunavirDrug
800 mg taken orally once daily. A protease inhibitor (PI).
RitonavirDrug
100 mg taken orally once daily. A protease inhibitor (PI).
AtazanavirDrug
300 mg taken orally once daily. A protease inhibitor (PI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Probability of First Virologic Failure by Week 96Time frame: From study entry to week 96
- Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96Time frame: From study entry to week 96
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Therapeutics CRS
Birmingham, Alabama
Miller Children's Hospital
Long Beach, California
USC CRS
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
Stanford CRS
Palo Alto, California
Ucsd, Avrc Crs
San Diego, California
Ucsf Aids Crs
San Francisco, California
Harbor-UCLA Med. Ctr. CRS
Torrance, California
University of Colorado Hospital CRS
Aurora, Colorado
Denver Public Health CRS
Denver, Colorado
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia
Howard Univ. Washington DC NICHD CRS
Washington D.C., District of Columbia
South Florida Childrens Diagnostic & Treatment Cen (5055)
Fort Lauderdale, Florida
University of Florida Jacksonville (5051)
Jacksonville, Florida
Univ. of Miami AIDS CRS
Miami, Florida
The Ponce de Leon Center CRS
Atlanta, Georgia
Northwestern University CRS
Chicago, Illinois
Rush Univ. Med. Ctr. ACTG CRS
Chicago, Illinois
Tulane University New Orleans NICHD CRS (5095)
New Orleans, Louisiana
IHV Baltimore Treatment CRS
Baltimore, Maryland
Johns Hopkins Adult AIDS CRS
Baltimore, Maryland
Massachusetts General Hospital CRS
Boston, Massachusetts
Brigham and Women's Hosp. ACTG CRS
Boston, Massachusetts
Bmc Actg Crs
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr., ACTG CRS
Boston, Massachusetts
Wayne State Univ. CRS
Detroit, Michigan
Henry Ford Hosp. CRS
Detroit, Michigan
Washington U CRS
St Louis, Missouri
Cooper Univ. Hosp. CRS
Camden, New Jersey
New Jersey Medical School- Adult Clinical Research Ctr. CRS
Newark, New Jersey
Cornell CRS
New York, New York
NY Univ. HIV/AIDS CRS
New York, New York
Metropolitan Hospital
New York, New York
HIV Prevention & Treatment CRS
New York, New York
AIDS Care CRS
Rochester, New York
Univ. of Rochester ACTG CRS
Rochester, New York
SUNY Stony Brook NICHD CRS (5040)
Stony Brook, New York
Bronx-Lebanon Hosp. Ctr. CRS
The Bronx, New York
Unc Aids Crs
Chapel Hill, North Carolina
Duke Univ. Med. Ctr. Adult CRS
Durham, North Carolina
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.